ライフサイエンスコーパス: rivastigmine

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します

1 histochemistry in the presence or absence of rivastigmine.

2 Almost twice as many patients on rivastigmine (37, 63%), than on placebo (18, 30%), showe

3 to placebo (59 assessed), those assigned to rivastigmine (55 assessed) had improved step time variab

4 Rivastigmine 6-12 mg daily produces statistically and cl

5 ested the effects of acute administration of rivastigmine, a central cholinesterase inhibitor, on pat

6 Rivastigmine, a cholinesterase inhibitor, was tested in

7 e present experiment assessed the ability of rivastigmine, a clinically utilized agent that inhibits

8 ntamine, the acetylcholinesterase inhibitors rivastigmine and donepezil did not potentiate nAChR-medi

9 cribed inhibition of acetylcholinesterase by rivastigmine and other carbamates as well as acylation o

10 ter drug discontinuation differences between rivastigmine and placebo tended to disappear.

11 cacy measures differed significantly between rivastigmine and placebo.

12 y was applied to the asymmetric synthesis of rivastigmine and the formal synthesis of several other p

13 Three donepezil, two galantamine, one rivastigmine, and two memantine trials, comprising 3093

14 Rivastigmine, but not donepezil, was associated with gre

15 Rivastigmine can improve gait stability and might reduce

16 Individuals were given up to 12 mg rivastigmine daily or placebo for 20 weeks, followed by

17 The cholinesterase inhibitors rivastigmine, donepezil, and metrifonate, which are devo

18 ndicated beneficial effects of donepezil and rivastigmine for cognitive and psychiatric symptoms.

19 130 patients and randomly assigned 65 to the rivastigmine group and 65 to the placebo group.

20 estinal side-effects were more common in the rivastigmine group than in the placebo group (p<0.0001);

21 o group (p<0.0001); 20 (31%) patients in the rivastigmine group versus three (5%) in the placebo grou

22 nd have implications for the recent trial of rivastigmine in sepsis-associated delirium.

23 Rivastigmine inhibited acetylcholinesterase in all posit

24 like other cholinesterase inhibitors tested, rivastigmine inhibited cholinesterases in normal and pat

25 In conclusion, rivastigmine is a potent inhibitor of acetylcholinestera

26 hus, at the therapeutic concentrations used, rivastigmine is likely to result in inhibition of pathol

27 nit randomly assigned (1:1) patients to oral rivastigmine or placebo capsules (both taken twice a day

28 In contrast, rivastigmine resulted in complete inhibition of butyrylc

29 use of pharmacologic agents (dexamethasone, rivastigmine, risperidone, ketamine, dexmedetomidine, pr

30 ng, anorexia) were seen more frequently with rivastigmine than with placebo, but safety and tolerabil

31 mean difference (95% CI -2.15 to -0.05) for rivastigmine to -2.17 for 10 mg daily donepezil (95% CI

32 hese findings and show cost-effectiveness of rivastigmine treatment.

33 The potency of rivastigmine was compared with those of other specific i

34 Rivastigmine was equipotent to the specific acetylcholin

35 Rivastigmine was uptitrated from 3 mg per day to the tar

36 Patients taking rivastigmine were significantly less apathetic and anxio

37 icit with the acetylcholinesterase inhibitor rivastigmine would reduce gait variability.

WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。